Ranbaxy Misses Out on First-Day Launch of Hypertension Drug’s Generic Version

Ranbaxy LaboratoriesBSE has missed out on the “first-day launch” of its generic version of Novartis’ blockbuster hypertension drug Diovan (valsartan) in the U.S., as it is yet to get the FDA’s approval for the generic version of the drug.
The Economic Times